<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">Mol. Cancer</journal-id>
      <journal-title-group>
        <journal-title>Molecular Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1476-4598</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23849082</article-id>
      <article-id pub-id-type="pmc">3717050</article-id>
      <article-id pub-id-type="publisher-id">1476-4598-12-73</article-id>
      <article-id pub-id-type="doi">10.1186/1476-4598-12-73</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The evolution of malignant and reactive &#x3B3;&#x3B4;&#x2009;+&#x2009;T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Chen</surname>
            <given-names>Shaohua</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>jnshaohuachen@163.com</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Huang</surname>
            <given-names>Xin</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>huangmingxin2001@sina.com</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Zheng</surname>
            <given-names>Haitao</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>Avery-2006@163.com</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Geng</surname>
            <given-names>Suxia</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>gsx76@126.com</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Wu</surname>
            <given-names>Xiuli</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>siulier@163.com</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Yang</surname>
            <given-names>Lijian</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>jnyanglijian@163.com</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Weng</surname>
            <given-names>Jianyu</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>wsswjy@sina.com</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A8">
          <name>
            <surname>Du</surname>
            <given-names>Xin</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>miyadu@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A9">
          <name>
            <surname>Li</surname>
            <given-names>Yangqiu</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>yangqiuli@hotmail.com</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, 510632, China</aff>
      <aff id="I2"><label>2</label>Institute of Hematology, Medical College, Jinan University, Guangzhou, 510632, China</aff>
      <aff id="I3"><label>3</label>Department of Hematology, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, 510080, China</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>7</month>
        <year>2013</year>
      </pub-date>
      <volume>12</volume>
      <fpage>73</fpage>
      <lpage>73</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>4</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>7</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 Chen et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Chen et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.molecular-cancer.com/content/12/1/73"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>To improve the outcome of patients with T-cell acute lymphoblastic leukemia (T-ALL), characterization of the biological features of T-ALL blast cells and the immune status of patients with T-ALL is needed to identify specific therapeutic strategies.</p>
        </sec>
        <sec>
          <title>Findings</title>
          <p>Using a novel approach based on the combination of fine-tiling comparative genomic hybridization (FT-CGH) and ligation-mediated PCR (LM-PCR), we molecularly identified a malignant &#x3B3;&#x3B4;&#x2009;+&#x2009;T cell clone with a V&#x3B4;5D&#x3B4;2J&#x3B4;1 rearrangement that was paired with a T cell receptor (TCR) V&#x3B3;I and comprised a V&#x3B3;1V&#x3B4;5 T cell clone in a relapse T-ALL patient. This malignant V&#x3B4;5 T cell clone disappeared after chemotherapy, but the clone was detected again when disease relapsed post allogeneic hematopoietic stem cell transplantation (allo-HSCT) at 100&#xA0;weeks. Using PCR and GeneScan analyses, the distribution and clonality of the TCR V&#x3B3; and V&#x3B4; subfamilies were examined before and after allo-HSCT in the patient. A reactive T cell clone with a V&#x3B4;4D&#x3B4;3J&#x3B4;1 rearrangement was identified in all samples taken at different time points (i.e., 4, 8, 68, 100 and 108&#xA0;weeks after allo-HSCT). The expression of this V&#x3B4;4+ T cell clone was higher in the patient during complete remission (CR) post allo-HSCT and at disease relapse.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>This study established a sensitive methodology to detect T cell subclones, which may be used to monitor minimal residual disease and immune reconstitution.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>&#x3B3;&#x3B4; T cell clone</kwd>
        <kwd>T-ALL</kwd>
        <kwd>FT-CGH</kwd>
        <kwd>TCR</kwd>
        <kwd>Allo-HSCT</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Findings</title>
      <p>T-cell acute lymphoblastic leukemia (T-ALL) comprises 25% of adult ALL cases, and its outcome is poorly understood. Among patients with T-ALL, approximately 40% achieve long-term remission [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the best options for curing T-ALL. However, many patients cannot find an HLA-matched donor; therefore, haploidentical/mismatched HSCTs may be an alternative treatment for T-ALL [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. The high T-ALL failure rate is mainly the result of an insufficient understanding of T-ALL biology, which hampers the identification of reliable prognostic factors that enable appropriate therapy adjustment [<xref ref-type="bibr" rid="B1">1</xref>]. To improve T-ALL outcome, characterization of the biological features of T-ALL blast cells and the immune status of patients is needed to design specific therapeutic strategies [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. T-ALL is generally considered to be a clonal disorder that arises from the expansion of committed lymphoid precursors, and leukemic clones in different patients vary due to the T cell receptor (TCR) gene rearrangements that occur during T-cell differentiation [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Moreover, TCR rearrangements also provide different recombination breakpoints that lead to the creation of fusion genes [<xref ref-type="bibr" rid="B12">12</xref>]. TCR rearrangement analysis may be used to determine T-ALL immunogenetic characteristics, and TCR rearrangements may be characterized by leukemia antigen-reactive T cell clones, which are thought to be specific to anti-leukemic cytotoxic T cells [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>].</p>
      <p>In this study, using a novel approach based on the combination of fine-tiling comparative genomic hybridization (FT-CGH) and ligation-mediated PCR (LM-PCR) [<xref ref-type="bibr" rid="B15">15</xref>], which combines PCR and the GeneScan techniques [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>], we molecularly characterized the malignant and reactive &#x3B3;&#x3B4;&#x2009;+&#x2009;T cell clones in a patient with T-ALL before and after relapse 100&#xA0;weeks post allo-HSCT.</p>
      <p>A 25-year-old male patient was diagnosed with relapse T-ALL in November 2009. The diagnosis was based on cytomorphology, immunohistochemistry and cytoimmunological analyses. He underwent salvage chemotherapies for the next 3&#xA0;months. However, his response assessments were partial remission (PR), minor remission (NR), and NR. In March 2010, the patient received an HLA-identical sibling peripheral blood (PB) HSCT after a conditioning regimen in addition to cyclosporin (CsA) in combination with a short course of mycophenolate mofetil (MMF) and four doses of methotrexate (MTX) for graft versus host disease (GVHD) prophylaxis as previously described [<xref ref-type="bibr" rid="B18">18</xref>]. Lumbar puncture and intrathecal chemotherapy were performed as normal. Four weeks after transplantation, the patient was stricken with fever, diarrhea, and a rash, which is considered Grade II GVHD. Eight weeks after transplantation, the GVHD was controlled with methylprednisolone (MP) and CsA treatment. Central nervous system leukemia (CNSL) was found 20&#xA0;weeks post transplantation, and intrathecal chemotherapy and radiotherapy of the head were then applied. The patient achieved complete remission (CR) in the bone marrow and was consistently normal upon cerebrospinal fluid examination at 40, 52, and 68&#xA0;weeks after transplantation. However, relapse was discovered 100&#xA0;weeks after transplantation, and he underwent chemotherapy over the next two months and achieved remission. The treatment process is summarized in Table&#xA0;<xref ref-type="table" rid="T1">1</xref>, and the details of the regimens used are summarized in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S1. As of this reporting, the patient remains in follow-up. Blood samples were collected with informed consent when the patient was diagnosed with relapse T-ALL before transplantation and at 4, 8, 68, 100 and 108&#xA0;weeks post transplantation (Table&#xA0;<xref ref-type="table" rid="T2">2</xref> and Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S2). PB was collected in an EDTA-containing collection tube, and PB mononuclear cells (PBMCs) were separated using the Ficoll-Hypaque gradient centrifugation method. All procedures were conducted in accordance with the guidelines of the Medical Ethics committees of Guangdong General Hospital according the guidelines of the health bureau of Guangdong Province, China.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Clinical therapy details for the patient with relapse T-ALL</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th rowspan="2" align="left" valign="top">
                <bold>Therapy date</bold>
              </th>
              <th rowspan="2" align="center" valign="top">
                <bold>Therapy</bold>
              </th>
              <th rowspan="2" align="center" valign="top">
                <bold>Response</bold>
              </th>
              <th align="center" valign="bottom">
                <bold>Blast cells (%) post-treatment</bold>
                <hr/>
              </th>
              <th rowspan="2" align="center" valign="top">
                <bold>CSF</bold>
              </th>
              <th rowspan="2" align="center" valign="top">
                <bold>Intrathecal chemotherapy</bold>
              </th>
            </tr>
            <tr>
              <th align="center">
                <bold>BM / PB</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">18.11-01.12.2009<hr/></td>
              <td align="center" valign="bottom">CTX, VCR, ADM, DXM<hr/></td>
              <td align="center" valign="bottom">PR<hr/></td>
              <td align="center" valign="bottom">11 / 3<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">MTX + DXM<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">18.12-22.12.2009<hr/></td>
              <td align="center" valign="bottom">MTX, Ara-c , DXM<hr/></td>
              <td align="center" valign="bottom">NR<hr/></td>
              <td align="center" valign="bottom">37 / 3<hr/></td>
              <td align="center" valign="bottom">&#xA0;<hr/></td>
              <td align="center" valign="bottom">&#xA0;<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">25.01-30.01.2010<hr/></td>
              <td align="center" valign="bottom">CTX, Ara-c, TPT<hr/></td>
              <td align="center" valign="bottom">NR<hr/></td>
              <td align="center" valign="bottom">47 / 1<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">Ara-c + DXM<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">05.03.2010<hr/></td>
              <td align="center" valign="bottom">Allo-HSCT (conditioning regimen: Flu, BU/CY)<hr/></td>
              <td align="center" valign="bottom">CR<hr/></td>
              <td align="center" valign="bottom">1 / 0<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">MTX + DXM<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">13.04.2010<hr/></td>
              <td align="center" valign="bottom">CsA, MP<hr/></td>
              <td align="center" valign="bottom">GVHD (Grade II)<hr/></td>
              <td align="center" valign="bottom">0.5 / 0<hr/></td>
              <td align="center" valign="bottom">&#xA0;<hr/></td>
              <td align="center" valign="bottom">&#xA0;<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">13.05.2010<hr/></td>
              <td align="center" valign="bottom">CsA, MP<hr/></td>
              <td align="center" valign="bottom">GVHD under control<hr/></td>
              <td align="center" valign="bottom">1.5 / 0<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">MTX + DXM<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">12.08.2010- 07.01.2011<hr/></td>
              <td align="center" valign="bottom">Radiotherapy<hr/></td>
              <td align="center" valign="bottom">CNSL cured<hr/></td>
              <td align="center" valign="bottom">0 / 0<hr/></td>
              <td align="center" valign="bottom">+<hr/></td>
              <td align="center" valign="bottom">(Ara-c + MTX + DXM) x 8 times<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">26.04-21.05.2012<hr/></td>
              <td align="center" valign="bottom">VDS, NVT, L-ASPDXM<hr/></td>
              <td align="center" valign="bottom">Relapse, CR<hr/></td>
              <td align="center" valign="bottom">3 / 0<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">MTX + DXM (03.05 2012) Ara-c + DXM (25.05.2012)<hr/></td>
            </tr>
            <tr>
              <td align="left">08.06-06.07.2012</td>
              <td align="center">VCR, NVT, L-ASP, DXM, CTX</td>
              <td align="center">CR</td>
              <td align="center">1 / 0</td>
              <td align="center">-</td>
              <td align="center">&#xA0;</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>Notes: <italic>ADM</italic> adramycin, <italic>Ara-c</italic> cytarabine, <italic>BM</italic> bone marrow, <italic>BU</italic> busulfan, <italic>CNSL</italic> central nervous system leukemia, <italic>CsA</italic> cyclosporin, <italic>CSF</italic> cerebrospinal fluid,<italic>CTX</italic> cyclophosphamide, <italic>CR</italic> complete remission, <italic>CY</italic> cyclophosphamide, <italic>DXM</italic> dexamethasone, <italic>Flu</italic> fludarabine, <italic>L-ASP</italic> l-asparaginase, <italic>MP</italic> methylprednisolone,<italic>MTX</italic> Methotrexate, <italic>NR</italic> minor remission, <italic>NVT</italic> mitoxantrone, <italic>PR</italic> partial remission, <italic>PB</italic> peripheral blood, <italic>TPT</italic> Topotecan, <italic>VCR</italic> vincristine, <italic>VDS</italic> Vindesine.</p>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="T2">
        <label>Table 2</label>
        <caption>
          <p>Clinical details of the collected samples</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>No.</bold>
              </th>
              <th align="left">
                <bold>Diagnosis</bold>
              </th>
              <th align="left">
                <bold>Disease status</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">A<hr/></td>
              <td align="left" valign="bottom">Relapse<hr/></td>
              <td align="left" valign="bottom">Relapse<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">B<hr/></td>
              <td align="left" valign="bottom">Pre allo-HSCT<hr/></td>
              <td align="left" valign="bottom">NR<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">C<hr/></td>
              <td align="left" valign="bottom">4&#xA0;W post allo-HSCT<hr/></td>
              <td align="left" valign="bottom">CR<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">D<hr/></td>
              <td align="left" valign="bottom">8&#xA0;W post allo-HSCT<hr/></td>
              <td align="left" valign="bottom">CR<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">E<hr/></td>
              <td align="left" valign="bottom">68&#xA0;W post allo-HSCT<hr/></td>
              <td align="left" valign="bottom">CR<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">F<hr/></td>
              <td align="left" valign="bottom">100&#xA0;W<hr/></td>
              <td align="left" valign="bottom">Relapse<hr/></td>
            </tr>
            <tr>
              <td align="left">G</td>
              <td align="left">108&#xA0;W</td>
              <td align="left">MRD</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>Notes: allo-HSCT: <italic>CR</italic> complete remission,</p>
          <p><italic>MTD</italic> minimal residual disease, <italic>NR</italic> minor remission.</p>
        </table-wrap-foot>
      </table-wrap>
      <sec>
        <title>Malignant T-ALL clone</title>
        <p>To characterize the cellular T-ALL features and the T cell clonality at different time points before and after allo-HSCT and at relapse post allo-HSCT, which may identify a factor associated with outcome, we analyzed the TCR breakpoint loci to identify chromosomal translocations and malignant T cell clones by the FT-CGH, LM-PCR, RT-PCT and GeneScan techniques [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>].</p>
        <p>FT-CGH using overlapping oligonucleotides designed to cover an entire genomic region of interest is a valuable tool for high-resolution chromosomal breakpoint characterization [<xref ref-type="bibr" rid="B15">15</xref>]. To achieve high resolution CGH (&lt;1&#xA0;kb), which is necessary for subsequent <italic>in vitro</italic> DNA amplification, a custom designed high-density, fine-tiling long oligonucleotide array consisting of 385,000 oligonucleotides 40&#x2013;60&#xA0;bp in length was prepared using Maskless Array Synthesizer (MAS) technology (NimbleGen Systems; Reykjavik, Iceland). This array, covering 24&#xA0;Mb of genome, was selected using the human genome browser hg18 assembly (University of California, Santa Cruz). The array included TCR &#x3B1;&#x3B4; and IgH loci, which are located on chromosome 14q11 (Chr14: 21,130 -22,130&#xA0;kb) and 14q32 (Chr14: 105,080 -106,360&#xA0;kb), respectively, and known to be frequently involved in chromosomal alterations in lymphoid malignancies. The neighboring oligonucleotides with an average distance of 63&#xA0;bp were grouped in 200, 400, and 1,000&#xA0;bp clusters. After normalization with reference DNA from the HEK293 T cell line, the mean fluorescence was analyzed using the SignalMap software (NimbleGen) [<xref ref-type="bibr" rid="B15">15</xref>].</p>
        <p>FT-CGH analysis of the TCR &#x3B1;&#x3B4; locus (Chr 14: 21,130-22,130) from the T-ALL sample revealed breakpoints at the 21,700&#xA0;kb (TCR V&#x3B4;5) and 22,000&#xA0;kb (TCR J&#x3B4;1) loci (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>A). LM-PCR using nested forward primers specific to the TCR V&#x3B4;5 locus revealed a normal rearrangement i.e., a TCR V&#x3B4;5 to J&#x3B4;1 rearrangement. Direct sequencing of these LM-PCR products demonstrated the following details of the V&#x3B4;5D&#x3B4;2J&#x3B4;1 rearrangement: the V&#x3B4;5 breakpoint is located in chromosome 14 at position 21,701,606 and the J&#x3B4;1 breakpoint is located in chromosome 14 at position 21,988,926 (Figures&#xA0;<xref ref-type="fig" rid="F1">1</xref>B and C). To confirm this TCR rearrangement, we used PCR to detect the V&#x3B4;5 and J&#x3B4;1 loci with specific primers and undigested genomic DNA. Thus, two 14q11.2 (TCR &#x3B1;&#x3B4;) chromosome breakpoints were characterized as a TCR idiotype rearrangement. Therefore, it may be concluded that there were no additional breakpoints providing a recombination point for the TCR &#x3B1;&#x3B4; locus-related chromosomal translocation because the translocation of proto-oncogenes to TCR loci most likely occurred as the cell attempted to undergo V(D)J recombination, and it is likely that these translocations arise as a mistake in this process, depending on the location of the breakpoint in the receptor locus [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. Using RT-PCR, GeneScan, and sequencing analysis, the V&#x3B4;5D&#x3B4;2J&#x3B4;1 rearrangement was confirmed to be monoclonal (The information of the primers used for TCR V&#x3B4;5-PCR was listed in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S3). Monoclonally expanded V&#x3B4;5 T cells, which were presumed to pair with the TCR V&#x3B3;I, comprised a V&#x3B3;IV&#x3B4;5 T cell clone (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>A). Significantly, this malignant monoclone was lost after chemotherapy and allo-HSCT, but there was a gain in polyclonal V&#x3B4;5 T cells, which may pair with V&#x3B3;II T cells and comprise many normal V&#x3B3;IIV&#x3B4;5 T cell clones (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>B) that arise from normal random V(D)J rearrangements [<xref ref-type="bibr" rid="B1">1</xref>]. Although the GeneScan results revealed biclonal V&#x3B4;5 T cells in the allo-HSCT sample taken after 68&#xA0;weeks, these T cell clones were different from the malignant clone (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>). The malignant monoclonal V&#x3B4;5 product was 466&#xA0;bp (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>A), while both of the clonal V&#x3B4;5 products from the post transplantation sample were 459 and 477&#xA0;bp (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>E). Moreover, the malignant monoclonal V&#x3B4;5 clone reemerged 100&#xA0;weeks after allo-HSCT treatment (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>F), a time at which the patient underwent relapse, and the V&#x3B4;5 subfamily also included an oligoclone 108&#xA0;weeks after allo-HSCT (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>G), which was after chemotherapy and when the patient achieved remission. The CDR3 sequence of the V&#x3B4;5 clones at diagnosis and 100 and 108&#xA0;weeks post allo-HSCT were determined, and the polyclonal and biclonal V&#x3B4;5 T cell clones were found to contain different CDR3 sequences with different sizes. The V&#x3B4; subfamily members preferentially expressed in PB from healthy and T-ALL clones include V&#x3B4;1 and V&#x3B4;2, while the V&#x3B4;5 clone was reported to be rare [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. Thus, this malignant T cell clone may serve as a biomarker for the detection of minimal residual disease. Indeed, a malignant V&#x3B4;5 clone containing the same sequence was found at disease relapse 100&#xA0;weeks post allo-HSCT. Using quantitative real-time PCR [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>], we found that the expression level of the malignant V&#x3B4;5+ T cell clone was high at diagnosis and low when disease relapse was detected. In addition, the V&#x3B4;5 expression level declined even further after chemotherapy at 108&#xA0;weeks when the disease achieved remission with minimal residual disease (i.e., 4% blast cells in the bone marrow) (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>). These data further indicate the significance of dynamically monitoring malignant T cell clones to molecularly identify relapse, which may provide evidence for commencing treatments such as preventive anti-leukemia therapy to clinically inhibit disease relapse.</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p><bold>One TCR </bold><bold>&#x3B4; </bold><bold>clone was identified by FT-CGH, LM-PCR and sequencing in a T-ALL case, and a V</bold><bold>&#x3B4;</bold><bold>5D</bold><bold>&#x3B4;</bold><bold>2J</bold><bold>&#x3B4;</bold><bold>1 rearrangement was confirmed. A:</bold> FT-CGH analysis results for the TCR &#x3B1;&#x3B4; locus in chromosome 14 with arrows indicating the breakpoints. <bold>B:</bold> Comparison of the GenBank sequences within the V&#x3B4;5, D&#x3B4;2, and J&#x3B4;1 segments. <bold>C:</bold> Sequence of the V&#x3B4;5D&#x3B4;2J&#x3B4;1 splice junction from a purified LM-PCR product. The sequences within the ellipse indicate the CDR3 segment including the D&#x3B4;2 and N regions.</p>
          </caption>
          <graphic xlink:href="1476-4598-12-73-1"/>
        </fig>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p><bold>The distribution and clonality of the TCR V</bold>&#x3B3; <bold>and V</bold>&#x3B4; <bold>subfamily T cells in a patient with T-ALL at different time points before and after allo-HSCT. A:</bold> T-ALL relapse, <bold>B:</bold> pre-HSCT, <bold>C:</bold> 4&#xA0;weeks post allo-HSCT, <bold>D:</bold> 8&#xA0;weeks post allo-HSCT, <bold>E:</bold> 68&#xA0;weeks post allo-HSCT, <bold>F:</bold> 100&#xA0;weeks post allo-HSCT and disease relapse, and <bold>G:</bold> 108&#xA0;weeks post allo-HSCT and after one cycle of chemotherapy. The monoclonal V&#x3B4;5 subfamily could be found in samples <bold>A</bold>, <bold>F</bold>, and <bold>G</bold>, and the oligoclonal V&#x3B4;4 subfamily could be identified in samples <bold>C</bold> through <bold>G</bold>.</p>
          </caption>
          <graphic xlink:href="1476-4598-12-73-2"/>
        </fig>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <p><bold>The clonality and size of V</bold><bold>&#x3B4;</bold><bold>5 T cells in a patient with T-ALL at different time points.</bold> V&#x3B4;5 T cell clonality was measured at different time points including the following: <bold>A:</bold> relapse before allo-HSCT (the monoclonal V&#x3B4;5 product size was 466&#xA0;bp), <bold>B:</bold> pre-HSCT, <bold>C:</bold> 4&#xA0;weeks post allo-HSCT, <bold>D:</bold> 8&#xA0;weeks post allo-HSCT, <bold>E:</bold> 68&#xA0;weeks post allo-HSCT (the clonal V&#x3B4;5 products were 459 and 477&#xA0;bp, there were different from the malignant T cell clone with 466&#xA0;bp), <bold>F:</bold> 100&#xA0;weeks post allo-HSCT and disease relapse (a 466&#xA0;bp monoclonal V&#x3B4;5 product is again observed), and <bold>G:</bold> 108&#xA0;weeks post allo-HSCT and after one chemotherapy cycle with minimal residual disease (MRD) remaining (a 466&#xA0;bp monoclonal V&#x3B4;5 product is still detectable). <bold>H:</bold> The expression level of the monoclonal the V&#x3B4;5 gene at different time points (i.e., relapse before allo-HSCT, relapse at 100 and 108&#xA0;weeks post allo-HSCT and after one chemotherapy cycle with MRD remaining).</p>
          </caption>
          <graphic xlink:href="1476-4598-12-73-3"/>
        </fig>
        <p>The identification of malignant T-ALL cell clones was performed at different times using Southern blot, PCR, RT-PCR, GeneScan, FT-CGH, and next generation sequencing spectratyping [<xref ref-type="bibr" rid="B25">25</xref>]. The distribution profiles and clonality of the TCR repertoire in T cells could be characterized using RT-PCR and GeneScan [<xref ref-type="bibr" rid="B17">17</xref>]. While an advantage of the FT-CGH and LM-PCR techniques is that they can identify chromosomal breakpoints and unique, high percentage T cell clones in a sample, they cannot characterize the polyclonal TCR subfamily distribution or a small fraction of T cell clones [<xref ref-type="bibr" rid="B12">12</xref>]. The novel, exhaustive T cell repertoire sequencing technique can directly measure the TCR repertoire size of at least 1 million clonotypes [<xref ref-type="bibr" rid="B25">25</xref>]. Therefore, the combination of the FT-CGH, LM-PCR, PCR, and GeneScan techniques for characterizing T cell malignancies is an ideal serial method not only for identifying abnormal chromosome rearrangements in malignant T cell clones but also for detecting the evolution of malignant T cell clones for the diagnosis, prognosis, and evaluation of reactive T cell clones to characterize the immune status of patients and develop specific immunotherapies.</p>
      </sec>
      <sec>
        <title>Clonally expanded reactive T cell clone</title>
        <p>Numerous studies have demonstrated that specific clonally expanded T cells may be identified in the PB of patients with cancer and leukemia, demonstrating their specific anti-leukemic cytotoxicity in vitro [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B28">28</xref>]. Moreover, clonally expanded T cells may be derived from donor lymphocytes after allo-HSCT or donor lymphocyte infusion (DLI), which may increase survival following allo-HSCT in patients with advanced-stage acute leukemia [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. These clonally expanded T cells are derived from TCR &#x3B1;&#x3B2; or &#x3B3;&#x3B4; T cells [<xref ref-type="bibr" rid="B10">10</xref>]. Increasing data have demonstrated that &#x3B3;&#x3B4; T cells may be used to develop specific immunotherapies for patients with cancers such as bladder cancer and hepatocellular carcinoma [<xref ref-type="bibr" rid="B30">30</xref>]. After transplantation, the patient achieved CR, and the distribution and clonality of the TCR V&#x3B3; and V&#x3B4; subfamilies were examined. While a malignant V&#x3B4;5+ T cell clone was not detected, oligoclonally expanded V&#x3B4;4 subfamily T cells were identified in samples from all time points (i.e., 4, 8, 68, 100, and 108&#xA0;weeks post allo-HSCT) even after the patient underwent relapse (100&#xA0;weeks post allo-HSCT; Figures&#xA0;<xref ref-type="fig" rid="F2">2</xref>C to G). The TCR sequence of the V&#x3B4;4+ T cell clone was identified as V&#x3B4;4D&#x3B4;3J&#x3B4;1 by direct sequencing, and the same TCR rearrangement was confirmed in all samples from each of the time points post transplantation (Figure&#xA0;<xref ref-type="fig" rid="F4">4</xref>). The V&#x3B4;4+ T cell clone increased more than three-fold when the patient reached CR status post allo-HSCT. Interestingly, the V&#x3B4;4 expression level gradually increased 100 and 108&#xA0;weeks post allo-HSCT, which was when disease relapse occurred and after chemotherapy was given, respectively (Figure&#xA0;<xref ref-type="fig" rid="F5">5</xref>). This observation suggests that the increased V&#x3B4;4+ T cell clone may be a reactively expanded T cell clone that has specific anti-T-ALL function. Although the patient underwent GVHD 8&#xA0;weeks post transplantation, which was subsequently controlled, the continuously expanded T cell clone may be not related to GVHD. The higher proportion of V&#x3B4;4+ T cell clones in samples taken after disease relapse may further support the idea of its role as a reactively expanded anti-leukemia T-cell clone. These results are similar to findings by Meeh et al. who demonstrated that V&#x3B4;1+ T cells respond to acute leukemia [<xref ref-type="bibr" rid="B28">28</xref>]. However, further characterization of the biological functions of the V&#x3B4;4+ T cell clone is needed; the reactive T cell clone may be amplified and used to study adoptive anti-leukemia immunotherapy, moreover, the TCR V&#x3B4;4 and its pattner V&#x3B3; gene could be used for transfer and the modification of normal T cells for identification their anti-leukemia effect [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>].</p>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p><bold>The CDR3 sequence in the V</bold><bold>&#x3B4;</bold><bold>4D</bold><bold>&#x3B4;</bold><bold>3J</bold><bold>&#x3B4;</bold><bold>1 rearrangement. A:</bold> Sequence comparison of the V&#x3B4;4, D&#x3B4;3, and J&#x3B4;1 segments from GenBank; <bold>B:</bold> sequence of the V&#x3B4;4D&#x3B4;3J&#x3B4;1 splice junction.</p>
          </caption>
          <graphic xlink:href="1476-4598-12-73-4"/>
        </fig>
        <fig id="F5" position="float">
          <label>Figure 5</label>
          <caption>
            <p>
              <bold>The V</bold>
              <bold>&#x3B4;</bold>
              <bold>4 gene expression level at different time points post allo-HSCT.</bold>
            </p>
          </caption>
          <graphic xlink:href="1476-4598-12-73-5"/>
        </fig>
        <p>In summary, the evolution of malignant TCR &#x3B3;&#x3B4;&#x2009;+&#x2009;and reactive T cell clones was identified in a patient with relapse T-ALL before and after allo-HSCT and at relapse post allo-HSCT. The techniques used in this study establish the sensitive detection of malignant and reactive T cell clones, and the identified T cell clones may serve not only as biomarkers for minimal residual disease detection but also as anti-leukemia immune status indicators in patients who achieved CR.</p>
      </sec>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>YQL contributed to the concept development and study design. SHC performed the RT-PCR, GeneScan and real-time PCR analyses, HTZ performed LM-PCR, SXG prepared the RNA and cDNA, XLW and LJY prepared the PBMCs and DNA, and XH, JYW and XD were responsible for treatment of the patient and performed clinical data acquisition. YQL, SHC and XH coordinated the study and helped draft the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="S1">
        <caption>
          <title>Additional file 1: Table S1</title>
          <p> Details of Clinical therapy for the patient with relapse T-ALL. <bold>Table S2.</bold> Clinical patient characteristics. <bold>Table S3.</bold> List of primers used for the V&#x3B4;5 TCR PCR.</p>
        </caption>
        <media xlink:href="1476-4598-12-73-S1.doc">
          <caption>
            <p>Click here for file</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>This work was supported by grants from the National Natural Science Foundation of China (No. 30871091, 91129720 and 81270604), the Collaborated grant for HK-Macao-TW of the Ministry of Science and Technology (2012DFH30060), the Fundamental Research Funds for the Central Universities (No. 21610603, 21612116) and the Guangdong Science &amp; Technology Project (No. 2012B050600023).</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kraszeska</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Dawidowska</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Szczepa&#x144;ski</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Witt</surname>
            <given-names>M</given-names>
          </name>
          <article-title>T-cell acute lymphoblastic leukemia: recent molecular biology findings</article-title>
          <source>Br J Haematol</source>
          <year>2012</year>
          <volume>15</volume>
          <fpage>303</fpage>
          <lpage>315</lpage>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cleaver</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Beesley</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Firth</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Sturges</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>O&#x2019;Leary</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Hunger</surname>
            <given-names>SP</given-names>
          </name>
          <name>
            <surname>Baker</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Kees</surname>
            <given-names>UR</given-names>
          </name>
          <article-title>Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children&#x2019;s Oncology Group study</article-title>
          <source>Mol Cancer</source>
          <year>2010</year>
          <volume>9</volume>
          <fpage>105</fpage>
          <pub-id pub-id-type="doi">10.1186/1476-4598-9-105</pub-id>
          <pub-id pub-id-type="pmid">20459861</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Aifantis</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Raetz</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Buonamici</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Molecular pathogenesis of T-cell leukaemia and lymphoma</article-title>
          <source>Nat Rev Immunol</source>
          <year>2008</year>
          <volume>8</volume>
          <fpage>380</fpage>
          <lpage>390</lpage>
          <pub-id pub-id-type="doi">10.1038/nri2304</pub-id>
          <pub-id pub-id-type="pmid">18421304</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>LP</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>KY</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>YH</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>XH</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>XJ</given-names>
          </name>
          <article-title>Haploidentical/mismatched hematopoietic stem cell transplantation without in vitro T cell depletion for T cell acute lymphoblastic leukemia</article-title>
          <source>Biol Blood Marrow Transplant</source>
          <year>2012</year>
          <volume>18</volume>
          <fpage>716</fpage>
          <lpage>721</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbmt.2011.08.024</pub-id>
          <pub-id pub-id-type="pmid">21924223</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lv</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>X</given-names>
          </name>
          <article-title>Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go</article-title>
          <source>J Hematol Oncol</source>
          <year>2012</year>
          <volume>5</volume>
          <fpage>10</fpage>
          <pub-id pub-id-type="doi">10.1186/1756-8722-5-10</pub-id>
          <pub-id pub-id-type="pmid">22424172</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rezvany</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Jeddi-Tehrani</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wigzell</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Osterborg</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mellstedt</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>101</volume>
          <fpage>1063</fpage>
          <lpage>1070</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2002-03-0746</pub-id>
          <pub-id pub-id-type="pmid">12393705</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>De Rijke</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Fredrix</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Zoetbrood</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Scherpen</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Witteveen</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>De Witte</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>van de Wiel-Van Kemenade</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Dolstra</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <fpage>2885</fpage>
          <lpage>2891</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2002-11-3584</pub-id>
          <pub-id pub-id-type="pmid">12842998</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Zheng</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Niu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Geng</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Expression and distribution of the <italic>PPP2R5C</italic> gene in leukemia</article-title>
          <source>J Hematol Oncol</source>
          <year>2011</year>
          <volume>4</volume>
          <fpage>21</fpage>
          <pub-id pub-id-type="doi">10.1186/1756-8722-4-21</pub-id>
          <pub-id pub-id-type="pmid">21548944</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Huang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>The role of BCL11B in hematological malignancy</article-title>
          <source>Exp Hematol Oncol</source>
          <year>2012</year>
          <volume>1</volume>
          <fpage>22</fpage>
          <pub-id pub-id-type="doi">10.1186/2162-3619-1-22</pub-id>
          <pub-id pub-id-type="pmid">23211040</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bellone</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Svensson</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Zaslav</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Spitzer</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Golightly</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Celiker</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ahmed</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Pediatric T-cell prolymphocytic leukemia with an isolated 12(p13) deletion and aberrant CD117 expression</article-title>
          <source>Exp Hematol Oncol</source>
          <year>2012</year>
          <volume>1</volume>
          <fpage>7</fpage>
          <pub-id pub-id-type="doi">10.1186/2162-3619-1-7</pub-id>
          <pub-id pub-id-type="pmid">23211022</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Langerak</surname>
            <given-names>AW</given-names>
          </name>
          <name>
            <surname>van Den Beemd</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wolvers-Tettero</surname>
            <given-names>IL</given-names>
          </name>
          <name>
            <surname>Boor</surname>
            <given-names>PP</given-names>
          </name>
          <name>
            <surname>Van Lochem</surname>
            <given-names>EG</given-names>
          </name>
          <name>
            <surname>Hooijkaas</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Van Dongen</surname>
            <given-names>JJ</given-names>
          </name>
          <article-title>Molecular and flow cytometric analysis of the V&#x3B2; repertoire for clonality assessment in mature TCR&#x3B1;&#x3B2;T-cell proliferations</article-title>
          <source>Blood</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>165</fpage>
          <lpage>173</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V98.1.165</pub-id>
          <pub-id pub-id-type="pmid">11418476</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Przybylski</surname>
            <given-names>GK</given-names>
          </name>
          <name>
            <surname>Dik</surname>
            <given-names>WA</given-names>
          </name>
          <name>
            <surname>Wanzeck</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Grabarczyk</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Majunke</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Martin-Subero</surname>
            <given-names>JI</given-names>
          </name>
          <name>
            <surname>Siebert</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>D&#xF6;lken</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ludwig</surname>
            <given-names>WD</given-names>
          </name>
          <name>
            <surname>Verhaaf</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Van Dongen</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Schmidt</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Langerak</surname>
            <given-names>AW</given-names>
          </name>
          <article-title>Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL</article-title>
          <source>Leukemia</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>201</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.leu.2403619</pub-id>
          <pub-id pub-id-type="pmid">15668700</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tanaka-Harada</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kawakami</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Oka</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tsuboi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Katagiri</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Elisseeva</surname>
            <given-names>OA</given-names>
          </name>
          <name>
            <surname>Nishida</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Shirakata</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Hosen</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Fujiki</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Murao</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Nakajima</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Oji</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kanda</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kawase</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Sugiyama</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Biased usage of BV gene families of T-cell receptors of WT1 (Wilms&#x2019; tumor gene)-specific CD8+ T cells in patients with myeloid malignancies</article-title>
          <source>Cancer Sci</source>
          <year>2010</year>
          <volume>101</volume>
          <fpage>594</fpage>
          <lpage>600</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01453.x</pub-id>
          <pub-id pub-id-type="pmid">20132220</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Xing</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Tong</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>P</given-names>
          </name>
          <article-title>High doses of mother&#x2019;s lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood</article-title>
          <source>Blood</source>
          <year>2010</year>
          <volume>116</volume>
          <fpage>5941</fpage>
          <lpage>5947</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2010-01-262311</pub-id>
          <pub-id pub-id-type="pmid">20926772</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Przybylski</surname>
            <given-names>GK</given-names>
          </name>
          <name>
            <surname>Dittmann</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Grabarczyk</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>D&#xF6;lken</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Gesk</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Harder</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Landmann</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Siebert</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Schmidt</surname>
            <given-names>CA</given-names>
          </name>
          <article-title>Molecular characterization of a novel chromosomal translocation t(12;14)(q23;q11.2) in T-lymphoblastic lymphoma between the T-cell receptor delta-deleting elements (TRDREC and TRAJ61) and the hypothetical gene C12orf42</article-title>
          <source>Eur J Haematol</source>
          <year>2010</year>
          <volume>85</volume>
          <fpage>452</fpage>
          <lpage>456</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0609.2010.01508.x</pub-id>
          <pub-id pub-id-type="pmid">20659153</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>JYH</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>D</given-names>
          </name>
          <article-title><italic>TRGV</italic> and <italic>TRDV</italic> repertoire distribution and clonality of T cells from umbilical cord blood</article-title>
          <source>Transpl Immunol</source>
          <year>2009</year>
          <volume>20</volume>
          <fpage>155</fpage>
          <lpage>162</lpage>
          <pub-id pub-id-type="doi">10.1016/j.trim.2008.10.010</pub-id>
          <pub-id pub-id-type="pmid">19013241</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Puisieux</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Even</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Pannetier</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Jotereau</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Favrot</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kourilsky</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Oligoclonality of tumor-infiltrating lymphocytes from human melanomas</article-title>
          <source>J Immunol</source>
          <year>1994</year>
          <volume>153</volume>
          <fpage>2807</fpage>
          <lpage>2818</lpage>
          <pub-id pub-id-type="pmid">8077684</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Weng</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Geng</surname>
            <given-names>SX</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>YW</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>ZS</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>CW</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ling</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>CX</given-names>
          </name>
          <name>
            <surname>Liao</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Xiang</surname>
            <given-names>AP</given-names>
          </name>
          <article-title>Mesenchymal stem cell as salvage treatment for refractory chronic GVHD</article-title>
          <source>Bone Marrow Transplant</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>1732</fpage>
          <lpage>1740</lpage>
          <pub-id pub-id-type="doi">10.1038/bmt.2010.195</pub-id>
          <pub-id pub-id-type="pmid">20818445</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Vanura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Vrsalovic</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Le</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Marculescu</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kusec</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>J&#xE4;ger</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Nadel</surname>
            <given-names>B</given-names>
          </name>
          <article-title>V(D)J targeting mistakes occur at low frequency in acute lymphoblastic leukemia</article-title>
          <source>Genes Chromosomes Cancer</source>
          <year>2009</year>
          <volume>48</volume>
          <fpage>725</fpage>
          <lpage>736</lpage>
          <pub-id pub-id-type="doi">10.1002/gcc.20677</pub-id>
          <pub-id pub-id-type="pmid">19455608</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Thulien</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Belch</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Reiman</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Pilarski</surname>
            <given-names>LM</given-names>
          </name>
          <article-title>In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival</article-title>
          <source>Mol Cancer</source>
          <year>2012</year>
          <volume>11</volume>
          <fpage>78</fpage>
          <pub-id pub-id-type="doi">10.1186/1476-4598-11-78</pub-id>
          <pub-id pub-id-type="pmid">23083101</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kode</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Advani</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chiplunkar</surname>
            <given-names>S</given-names>
          </name>
          <article-title>T-cell receptor gamma and delta gene rearrangements in T-cell acute lymphoblastic leukemia in Indian patients</article-title>
          <source>Leuk Lymphoma</source>
          <year>2000</year>
          <volume>36</volume>
          <fpage>331</fpage>
          <lpage>338</lpage>
          <pub-id pub-id-type="doi">10.3109/10428190009148854</pub-id>
          <pub-id pub-id-type="pmid">10674905</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Langerak</surname>
            <given-names>AW</given-names>
          </name>
          <name>
            <surname>Wolvers-Tettero</surname>
            <given-names>IL</given-names>
          </name>
          <name>
            <surname>van den Beemd</surname>
            <given-names>MW</given-names>
          </name>
          <name>
            <surname>Van Wering</surname>
            <given-names>ER</given-names>
          </name>
          <name>
            <surname>Ludwig</surname>
            <given-names>WD</given-names>
          </name>
          <name>
            <surname>H&#xE4;hlen</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Necker</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Dongen</surname>
            <given-names>JJ</given-names>
          </name>
          <article-title>Immunophenotypic and immunogenotypic characteristics of TCR&#x3B3;&#x3B4;&#x2009;+&#x2009;T cell acute lymphoblastic leukemia</article-title>
          <source>Leukemia</source>
          <year>1999</year>
          <volume>13</volume>
          <fpage>206</fpage>
          <lpage>214</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.leu.2401276</pub-id>
          <pub-id pub-id-type="pmid">10025894</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Stams</surname>
            <given-names>WAG</given-names>
          </name>
          <name>
            <surname>Den Boer</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Beverloo</surname>
            <given-names>HB</given-names>
          </name>
          <name>
            <surname>Meijerink</surname>
            <given-names>JPP</given-names>
          </name>
          <name>
            <surname>Stigter</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Van Wering</surname>
            <given-names>ER</given-names>
          </name>
          <name>
            <surname>Janka-Schaub</surname>
            <given-names>GE</given-names>
          </name>
          <name>
            <surname>Slater</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Pieters</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)<sup>+</sup> pediatric ALL</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>101</volume>
          <fpage>2743</fpage>
          <lpage>2747</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2002-08-2446</pub-id>
          <pub-id pub-id-type="pmid">12433682</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zha</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Zhong</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Deficiency of CD3&#x3B3;, &#x3B4;, &#x3F5; and &#x3B6; expression in T-cells from AML patients</article-title>
          <source>Hematology</source>
          <year>2011</year>
          <volume>16</volume>
          <fpage>31</fpage>
          <lpage>36</lpage>
          <pub-id pub-id-type="doi">10.1179/102453311X12902908411832</pub-id>
          <pub-id pub-id-type="pmid">21269565</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Warren</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Freeman</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Choe</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Munro</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Webb</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Holt</surname>
            <given-names>RA</given-names>
          </name>
          <article-title>Exhaustive T-cell repertoire sequencing of human peripheral blood samples reveals signatures of antigen selection and a directly measured repertoire size of at least 1 million clonotypes</article-title>
          <source>Genome Res</source>
          <year>2011</year>
          <volume>21</volume>
          <fpage>790</fpage>
          <lpage>797</lpage>
          <pub-id pub-id-type="doi">10.1101/gr.115428.110</pub-id>
          <pub-id pub-id-type="pmid">21349924</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Zha</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Characterization of the CDR3 structure of V&#x3B2;21 T cell clone in patients with P210<sup>BCR-ABL</sup>-positive CML and B-ALL</article-title>
          <source>Hum Immunol</source>
          <year>2011</year>
          <volume>72</volume>
          <fpage>798</fpage>
          <lpage>804</lpage>
          <pub-id pub-id-type="doi">10.1016/j.humimm.2011.06.015</pub-id>
          <pub-id pub-id-type="pmid">21820025</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Yin</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Zha</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Generation of diffuse large B cell lymphoma-associated antigen-specific V&#x3B1;6/V&#x3B2;13&#x2009;+&#x2009;T cells by TCR gene transfer</article-title>
          <source>J Hematol Oncol</source>
          <year>2011</year>
          <volume>4</volume>
          <fpage>2</fpage>
          <pub-id pub-id-type="doi">10.1186/1756-8722-4-2</pub-id>
          <pub-id pub-id-type="pmid">21223579</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Meeh</surname>
            <given-names>PF</given-names>
          </name>
          <name>
            <surname>King</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>O&#x2019;Brien</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Muga</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Buchhalts</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Meuberg</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Lamb</surname>
            <given-names>LS</given-names>
            <suffix>Jr</suffix>
          </name>
          <article-title>Characterization of the &#x3B3;&#x3B4; T cell response to acute leukemia</article-title>
          <source>Cancer Immunol Immunother</source>
          <year>2006</year>
          <volume>55</volume>
          <fpage>1072</fpage>
          <lpage>1080</lpage>
          <pub-id pub-id-type="doi">10.1007/s00262-005-0094-6</pub-id>
          <pub-id pub-id-type="pmid">16328383</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>ZP</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>XJ</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>LP</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>KY</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>QF</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>DP</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>XJ</given-names>
          </name>
          <article-title>Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study</article-title>
          <source>Clin Transplant</source>
          <year>2012</year>
          <volume>26</volume>
          <fpage>635</fpage>
          <lpage>643</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1399-0012.2012.01626.x</pub-id>
          <pub-id pub-id-type="pmid">22515260</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cabillic</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Toutirais</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Lavou&#xE9;</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>de La Pinti&#xE8;re</surname>
            <given-names>CT</given-names>
          </name>
          <name>
            <surname>Daniel</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Rioux-Leclerc</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Turlin</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>M&#xF6;nkk&#xF6;nen</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>M&#xF6;nkk&#xF6;nen</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Boudjema</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Catros</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Bouet-Toussaint</surname>
            <given-names>F</given-names>
          </name>
          <article-title>Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients</article-title>
          <source>Cancer Immunol Immunother</source>
          <year>2010</year>
          <volume>59</volume>
          <fpage>1611</fpage>
          <lpage>1619</lpage>
          <pub-id pub-id-type="doi">10.1007/s00262-010-0887-0</pub-id>
          <pub-id pub-id-type="pmid">20582413</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Schmidt</surname>
            <given-names>CA</given-names>
          </name>
          <article-title>New insights into antigen specific immunotherapy for chronic myeloid leukemia</article-title>
          <source>Cancer Cell Int</source>
          <year>2012</year>
          <volume>12</volume>
          <fpage>52</fpage>
          <pub-id pub-id-type="doi">10.1186/1475-2867-12-52</pub-id>
          <pub-id pub-id-type="pmid">23241263</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kessels</surname>
            <given-names>HW</given-names>
          </name>
          <name>
            <surname>Wolkers</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>van den Boom</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>van der Valk</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Schumacher</surname>
            <given-names>TN</given-names>
          </name>
          <article-title>Immunotherapy through TCR gene transfer</article-title>
          <source>Nat Immunol</source>
          <year>2001</year>
          <volume>2</volume>
          <fpage>957</fpage>
          <lpage>961</lpage>
          <pub-id pub-id-type="doi">10.1038/ni1001-957</pub-id>
          <pub-id pub-id-type="pmid">11577349</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
